Table 3 OPA responses against individual pneumococcal vaccine serotypes and cross-reactive serotypes 6A and 19A 1 month after 3-dose primary vaccination (ATP immunogenicity cohort)
PHiD-CV group | Control group | |||||
|---|---|---|---|---|---|---|
PHiD-CV serotypes | N | % ≥ 8 (95% CI) | GMT (95% CI) | N | % ≥ 8 (95% CI) | GMT (95% CI) |
1 | 105 | 87.6 (79.8-93.2) | 83.0 (61.7-111.7) | 56 | 5.4 (1.1-14.9) | 5.0 (3.8-6.4) |
4 | 105 | 100 (96.5-100) | 892.5 (759.4-1049.0) | 55 | 5.5 (1.1-15.1) | 4.6 (3.9-5.5) |
5 | 105 | 95.2 (89.2-98.4) | 82.7 (65.4-104.4) | 56 | 3.6 (0.4-12.3) | 4.5 (3.8-5.2) |
6B | 103 | 85.4 (77.1-91.6) | 538.6 (346.0-838.3) | 54 | 9.3 (3.1-20.3) | 5.7 (4.1-7.9) |
7F | 105 | 100 (96.5-100) | 2733.0 (2188.3-3413.3) | 49 | 42.9 (28.8-57.8) | 31.5 (15.5-64.0) |
9V | 105 | 98.1 (93.3-99.8) | 1023.7 (784.8-1335.2) | 54 | 24.1 (13.5-37.6) | 8.4 (5.8-12.4) |
14 | 104 | 96.2 (90.4-98.9) | 1079.2 (776.0-1500.9) | 53 | 24.5 (13.8-38.3) | 8.9 (5.7-14.1) |
18C | 105 | 98.1 (93.3-99.8) | 617.6 (495.3-770.0) | 56 | 3.6 (0.4-12.3) | 4.4 (3.8-5.2) |
19F | 105 | 96.2 (90.5-99.0) | 358.3 (269.9-475.5) | 56 | 3.6 (0.4-12.3) | 4.6 (3.8-5.7) |
23F | 104 | 93.3 (86.6-97.3) | 881.8 (615.0-1264.4) | 53 | 9.4 (3.1-20.7) | 6.6 (4.2-10.3) |
Cross-reactive serotypes | ||||||
6A | 101 | 30.7 (21.9-40.7) | 14.1 (9.4-21.2) | 56 | 10.7 (4.0-21.9) | 6.1 (4.4-8.7) |
19A | 105 | 37.1 (27.9-47.1) | 11.0 (8.3-14.6) | 56 | 5.4 (1.1-14.9) | 4.3 (4.0-4.6) |